Skip to main content

Spironolactone did not reduce cardiac outcomes in symptomatic heart failure with preserved ejection fraction.

Publication ,  Journal Article
Kelly, J; Granger, CB
Published in: Ann Intern Med
October 21, 2014

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Ann Intern Med

DOI

EISSN

1539-3704

Publication Date

October 21, 2014

Volume

161

Issue

8

Start / End Page

JC6

Location

United States

Related Subject Headings

  • Spironolactone
  • Mineralocorticoid Receptor Antagonists
  • Male
  • Humans
  • Heart Failure
  • General & Internal Medicine
  • Female
  • 3202 Clinical sciences
  • 11 Medical and Health Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kelly, J., & Granger, C. B. (2014). Spironolactone did not reduce cardiac outcomes in symptomatic heart failure with preserved ejection fraction. Ann Intern Med, 161(8), JC6. https://doi.org/10.7326/0003-4819-161-8-201410210-02006
Kelly, Jacob, and Christopher B. Granger. “Spironolactone did not reduce cardiac outcomes in symptomatic heart failure with preserved ejection fraction.Ann Intern Med 161, no. 8 (October 21, 2014): JC6. https://doi.org/10.7326/0003-4819-161-8-201410210-02006.
Kelly, Jacob, and Christopher B. Granger. “Spironolactone did not reduce cardiac outcomes in symptomatic heart failure with preserved ejection fraction.Ann Intern Med, vol. 161, no. 8, Oct. 2014, p. JC6. Pubmed, doi:10.7326/0003-4819-161-8-201410210-02006.

Published In

Ann Intern Med

DOI

EISSN

1539-3704

Publication Date

October 21, 2014

Volume

161

Issue

8

Start / End Page

JC6

Location

United States

Related Subject Headings

  • Spironolactone
  • Mineralocorticoid Receptor Antagonists
  • Male
  • Humans
  • Heart Failure
  • General & Internal Medicine
  • Female
  • 3202 Clinical sciences
  • 11 Medical and Health Sciences